Navigation Links
Renovo Announces Results of Latest Phase 2 Studies of JUVISTA(R) (Human Recombinant TGFbeta3)

BASINGSTOKE, England and PHILADELPHIA, Pennysylvania, March 3 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP)(NASDAQ: SHPGY), the global specialty biopharmaceutical company, notes that Renovo Group plc, (LSE: RNVO) ("Renovo") has today announced the results of Renovo's latest Phase 2 studies of JUVISTA(R) (human recombinant TGFbeta3) in scar revision surgery (RN1001-319-1009) and in breast augmentation (RN1001-319-1010).

Renovo’s press release can be found on

The two trials announced by Renovo are part of a broad global Phase 2 clinical program to assess the safety, efficacy, dose and dose frequency of JUVISTA in a variety of surgical procedures.

Shire is at present assessing these latest results with all other results produced to date and plans to discuss these with the US Food and Drug Administration (FDA) in 2008 to determine the regulatory path forward in the United States.

Notes to Editors

Financial terms of the agreement with Renovo

Under the terms of the agreement with Renovo, Shire has the exclusive right to commercialize JUVISTA worldwide, with the exception of EU member states.

As previously announced, Shire will bear the cost of clinical trials designed specifically for obtaining US regulatory approval. Renovo will bear the costs of clinical trials designed specifically for obtaining EU regulatory approval. Shire and Renovo will share equally the costs of conducting global clinical trials that are designed for obtaining both US and EU regulatory approvals.

The financial terms of the agreement are geared to the success of the development and commercialization of JUVISTA. Shire has paid Renovo US$75 mil

Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BioWa Announces Expansion of License Agreement with Genentech for BioWas POTELLIGENT(R) Technology
2. DW Healthcare Partners Announces the Sale of Tandem Labs
3. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
4. Exelixis Announces March 4 Webcast of Presentation at the Susquehanna SIGnificant Options in Healthcare Conference
5. Announces Distribution of Spectra Intelligence Research
6. Kosan Announces Senior Management Changes and Clinical Portfolio Priorities
7. Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook
8. Wyeth Announces Executive Change in Finance Organization
9. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
10. Pharmacopeia Announces Management Team Changes
11. Reminder Webcast Alert: Transgenomic Inc. Announces Fourth Quarter 2007 Earnings Release Conference Call Webcast
Post Your Comments:
(Date:10/9/2015)... and ROCKVILLE, Md. , ... a privately-held biotechnology company developing next generation vaccines ... it has entered into an exclusive worldwide licensing ... for the treatment or prevention of any and ... the agreement, Immunomic Therapeutics will receive an upfront ...
(Date:10/9/2015)... ... October 09, 2015 , ... From blood to food ... those cells from their surroundings for research, diagnostics, and cell therapy—also known as ... this, Ann Arbor-based startup Akadeum Life Sciences is developing a radically ...
(Date:10/8/2015)... Oct. 8, 2015   Intrexon Corporation (NYSE: ... announced the appointment of Joseph L. Vaillancourt ... Nir Nimrodi who continues in his role ... Intrexon,s endeavors to generate sustainable, biologically based solutions to ... where he held a variety of key roles including, ...
(Date:10/8/2015)...  ATCC, the premier global biological materials resource and ... by The Michael J. Fox Foundation for Parkinson,s Research ... and biotechnology organizations committed to speed a cure for ... , and more than 5 million worldwide, have ... , and more than 5 million worldwide, have ...
Breaking Biology Technology:
... VICL ) today announced the enhancement of ... de Guttadauro as Vice President, Corporate,Development. Prior ... Director of,Strategy at Biogen Idec since February 2007, ... that company,s Zevalin,the first radioimmunotherapy product approved for ...
... Mulia Pangkuan Negeri -, TORONTO, Aug. 20 ... on developing simple blood-based biomarker tests for the,early ... that its co-founder and Chief Scientific Officer, Dr. ... Negeri (DMPN), a State Honour,given by the Governor ...
... Poised for Market Launch, KIRKLAND, Wash., Aug. 20 ... for the treatment of arterial,disease, today announced that it ... has started building its sales team in preparation for ... Recently Pathway moved from its old 10,000-square-foot facility ...
Cached Biology Technology:
(Date:9/28/2015)... Sept. 28, 2015 CLEAR, the ... its expedited traveler service is coming to ... travel, bringing a frictionless experience, serious speed ... "CLEAR offers our travelers an expedited ... said Jim Smith , Executive Director, ...
(Date:9/26/2015)... , Sept. 26th, 2015  Results of ... will be unveiled today at the Stanford Medicine ... Engagement Using iPad Dashboards, Connected Health Devices and ... of Pharmacy 3.0, will explain how senior patients ... data to their pharmacist via the TactioRPM remote ...
(Date:9/10/2015)... 10, 2015 Report Details The ... delivered upon previous expectations of revenues, consumer adoption and ... year in which wearables begin to achieve that mass ... the main reasons is the entrance of Apple to ... SmartWatches market, but the overall size of the wearable ...
Breaking Biology News(10 mins):
... LA JOLLA, Calif., September 25 2013 A new ... called medulloblastoma has been developed by researchers at Sanford-Burnham ... cellsthe cells that are critical for maintaining tumor growthand ... are essential for tumor progression. The process destroys the ...
... how their meat is sourced, with animal welfare ... many purchases. Unfortunately, many widely-used livestock production methods ... from the University of Cambridge has identified what ... silvopastoral systems which include shrubs and trees with ...
... , Sept. 25, 2013   GenoVive , an innovator ... against the emerging "globesity" epidemic through its development of ... on each individual,s unique metabolism.  "Weight Loss Designed by ... to customize an all natural meal and exercise program ...
Cached Biology News: